Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $10.80 Average PT from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $10.80.

Several research analysts recently issued reports on XERS shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Finally, Weiss Ratings raised shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th.

Xeris Biopharma Trading Up 1.8%

NASDAQ XERS opened at $6.13 on Friday. The stock has a market capitalization of $1.06 billion, a P/E ratio of -612.39 and a beta of 0.77. Xeris Biopharma has a 52-week low of $4.26 and a 52-week high of $10.08. The firm has a 50-day moving average price of $5.93 and a 200 day moving average price of $7.03. The company has a quick ratio of 1.57, a current ratio of 2.19 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $85.81 million during the quarter, compared to analysts’ expectations of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Equities research analysts expect that Xeris Biopharma will post 0.12 EPS for the current year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, Director James Aloysius Brady sold 10,834 shares of the stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $5.54, for a total value of $60,020.36. Following the completion of the transaction, the director directly owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. This trade represents a 10.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75. Following the completion of the transaction, the insider directly owned 1,226,507 shares of the company’s stock, valued at approximately $7,665,668.75. This trade represents a 1.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 60,835 shares of company stock valued at $388,194. 6.47% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC increased its holdings in Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after buying an additional 135,815 shares in the last quarter. State Street Corp increased its holdings in Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after buying an additional 378,595 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after buying an additional 185,063 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.